Copenhagen, Denmark – Demant, a global leader in hearing healthcare and parent company of renowned brands such as Oticon and Bernafon, has announced a comprehensive cost reduction program in response to a turbulent year characterized by softer industry-wide market growth and compressed profit margins. This strategic initiative includes the elimination of approximately 700 positions worldwide, a significant move designed to recalibrate the company’s cost structure and enhance long-term profitability. Despite the global scope of these reductions, Demant has provided assurances that its vital professional services and customer-facing roles within the United States hearing care market are expected to remain largely untouched, with the bulk of the cuts targeting administrative functions primarily outside the U.S.
The restructuring follows the release of Demant’s Annual Report 2025, which detailed the company’s full-year financial performance and outlined the necessity for a robust profitability initiative. The report highlighted a period of intense competition and macroeconomic uncertainties that have impacted consumer behavior across the global hearing aid market. While the company achieved 5% revenue growth for the fiscal year 2025 (2% organically), its Earnings Before Interest and Taxes (EBIT) before special items saw a decrease of approximately 7%, settling at DKK 3.960 billion (approximately US$626 million), resulting in an operating margin of 17.2%. This divergence between revenue growth and profit decline underscored the pressures necessitating immediate and decisive action.
The Rationale Behind the Restructuring
Demant’s decision to implement such a far-reaching cost reduction program stems directly from a confluence of challenging market dynamics observed throughout the fiscal year 2025. The company’s official statements, mirrored by industry-wide observations, consistently point to "macroeconomic uncertainties" as a primary driver for the downturn in market performance. These uncertainties have translated into a "reduced willingness to invest and resulting delayed purchases" among consumers, significantly impacting the hearing healthcare market, particularly in the critical U.S. segment.
Søren Nielsen, Demant’s CEO, elaborated on these challenges during a recent conversation at the U.S. launch of the Oticon Zeal product. He noted that even in Denmark, a market where approximately half the population receives hearing aids free of charge, market growth has been flat. Nielsen articulated the psychological barrier faced by consumers: "You don’t take the step [toward getting a hearing aid] if you’re not comfortable about how the world is going to develop." He added, "And we see that worldwide: uncertainty in all parts is causing people to hold back… so they’re just postponing purchases a little bit." This sentiment underscores a broader trend of consumer caution, where discretionary spending, even on essential health-related devices, is deferred in times of economic instability. The cumulative effect of these delays has created a highly competitive environment as manufacturers vie for a shrinking pool of immediate purchasers.
Financial Performance in 2025 and the Need for Action
Demant’s financial report for 2025 painted a nuanced picture of resilience amidst adversity. The 5% reported revenue growth, with 2% organic growth, indicated that the company managed to expand its top line despite the challenging environment. This performance allowed Demant to meet its twice-revised forecasts for the year, a testament to its market position and operational efforts. However, the accompanying decline in profitability signaled a critical area of concern. The 7% decrease in EBIT before special items, falling to DKK 3.960 billion (approximately US$626 million), coupled with a 17.2% operating margin, indicated that revenue growth was achieved at a higher cost or in a less profitable mix, leading to an erosion of earnings.
This "good news-bad news" scenario, where sales targets were met but profitability suffered, directly catalyzed the decision to initiate the comprehensive cost-saving program. The company recognized that sustained long-term success required not only maintaining market share but also optimizing its operational efficiency and cost base to weather ongoing market volatility and prepare for future growth. The program aims to "reset costs" after a period where industry conditions made traditional growth models less profitable.
Demant’s Strategic Response: The Cost Reduction Program
In response to these fiscal pressures, Demant has outlined a robust, multi-year cost reduction strategy designed to yield permanent, long-term savings through structural changes. This initiative is slated to be implemented over the next two years, with significant effects projected to materialize progressively. The company has identified several key "levers" through which these efficiencies will be achieved:
- Shifting Work to More Cost-Effective Locations: This involves a strategic reallocation of certain operational functions to regions or countries where labor and overhead costs are lower, leveraging global talent pools more efficiently.
- Prioritizing Activities: A rigorous review of all company activities will be undertaken to identify and eliminate non-essential tasks, streamline processes, and focus resources on core strategic objectives that deliver the highest value.
- Increasing Efforts to Lower Production Costs: This entails optimizing manufacturing processes, exploring new technologies, and improving supply chain management to reduce the per-unit cost of producing hearing aids and diagnostic equipment.
- Tightening Procurement: Demant will intensify its focus on procurement strategies, negotiating better terms with suppliers, consolidating purchasing power, and exploring alternative sourcing options to reduce material and component costs.
These structural changes are expected to result in a global workforce reduction of approximately 700 employees by 2026. Of these, 150 positions are anticipated to be cut within Demant’s home country of Denmark. The company projects that this comprehensive initiative will generate annual cost savings of around DKK 500 million (approximately US$79 million), with the full effect realized by 2028. Importantly, Demant anticipates achieving DKK 250 million (approximately US$39 million) of these savings as early as 2026, providing a timely boost to its financial performance.
Impact on the U.S. Market and Hearing Care Providers
A critical aspect of Demant’s restructuring plan, particularly for its North American stakeholders, is the assurance regarding the continuity of services in the U.S. market. A representative from Oticon US, with direct knowledge of the situation, conveyed to HearingTracker that the staff reductions are not expected to significantly impact the United States. Furthermore, hearing care providers in the U.S. will reportedly not experience cuts to essential customer-facing roles. This includes positions vital for ongoing business relationships and support, such as field representatives who interact directly with clinics, customer service personnel, and other related support functions crucial for product delivery, technical assistance, and professional education.
The spokesperson indicated that the bulk of the job cuts are primarily targeted at administrative positions outside the U.S. This strategic focus suggests that Demant is aiming to streamline its global corporate and back-office functions, reallocating costs and optimizing efficiency without disrupting the direct sales, service, and support networks that are fundamental to its market presence in key regions like the U.S. The company’s emphasis on protecting client-facing roles underscores its commitment to maintaining strong relationships with its network of audiologists and hearing aid specialists, recognizing their pivotal role in connecting Demant’s innovative products with end-users.
Broader Industry Context and Macroeconomic Pressures
){kind=logo}
Demant’s experience in 2025 is not an isolated incident but rather reflective of broader trends impacting the global hearing aid industry. Many recent financial reports from major hearing aid manufacturers have cited similar macroeconomic headwinds. Factors such as elevated inflation, rising interest rates, and geopolitical uncertainties have collectively dampened consumer confidence and purchasing power across various sectors. For the hearing aid market, this has manifested as "lower-than-normal growth," particularly evident in the U.S., which is one of the largest and most competitive markets globally.
The industry typically experiences steady growth driven by demographic trends, such as an aging population and increasing awareness of hearing health. However, economic downturns can cause consumers to postpone non-urgent medical purchases, including hearing aids. This delay creates a backlog of potential customers but also intensifies competition among manufacturers for immediate sales. The reported "flat or slightly negative growth in U.S. hearing aid sales" for 2025, as noted in Demant’s report, is a stark indicator of these pressures, compelling all market players to reassess their operational strategies.
The KIND Group Acquisition and Potential Synergies
Adding another layer to Demant’s strategic adjustments is its acquisition of KIND Group in 2025. KIND Group is one of Germany’s largest dispensing networks, boasting approximately 650 locations. While the original announcement did not explicitly link the KIND acquisition to the job cuts, it is a logical inference that such a significant corporate integration could lead to overlaps in administrative tasks, particularly in back-office and support functions. Mergers and acquisitions often involve a period of consolidation where redundant roles are identified and streamlined to achieve greater operational efficiency and cost synergies.
The KIND Group acquisition is expected to be a significant contributor to Demant’s future financial performance. For 2026, the company anticipates that KIND Group will contribute approximately DKK 300 million (approximately US$47 million) to its EBIT before special items. This highlights Demant’s strategy of not only optimizing its existing operations but also pursuing strategic growth opportunities through acquisitions that strengthen its market position and distribution channels. The integration of KIND Group, while potentially leading to some administrative rationalization, is ultimately aimed at enhancing Demant’s overall market reach and profitability in the long run.
Product Innovation and Market Outlook
Despite the current challenges and restructuring efforts, Demant remains committed to innovation and looks towards future growth, partly driven by new product introductions. The company recently launched the unique Oticon Zeal NXT instant-fit in-ear hearing aid. It debuted at EUHA in Germany in October and received a positive reception from attending hearing care professionals during its U.S. launch in Phoenix in January. This product, featuring modern connectivity and rechargeability, represents Demant’s continuous effort to bring advanced solutions to the market and cater to evolving consumer preferences. Market analysts are also speculating that Oticon may launch a new flagship product line later this year, further solidifying its innovation pipeline.
Looking ahead, Demant has provided a conservative outlook for the global hearing aid market. For 2026, the company assumes market value growth of 2-4%, describing this forecast as "temporarily below" its medium- to long-term assumptions, which typically range from 4-6% growth over the past decade. Despite this cautious market forecast, Demant is guiding for 3-6% organic growth for itself in 2026. It expects EBIT before special items to fall within the range of DKK 4,100–4,500 million (approximately US$648–711 million). This projected improvement in profitability is anticipated to be significantly bolstered by the ongoing profitability initiative, which is expected to contribute roughly DKK 250 million (approximately US$39 million) to EBIT before special items in 2026, with most of the benefit skewed towards the second half of the year as the restructuring actions gain full momentum. The contribution from the KIND Group acquisition will also play a crucial role in achieving these financial targets.
)
Historical Context and Demant’s Market Position
Demant has long stood as a titan in the global hearing healthcare sector. Beyond Oticon and Bernafon, its portfolio includes numerous leading manufacturers of diagnostic and specialized equipment, making it a comprehensive provider across the entire hearing care continuum. This diversified presence has historically provided a degree of resilience against market fluctuations. The company’s long-standing commitment to research and development has consistently positioned it at the forefront of technological advancements in hearing aid technology. The current restructuring, therefore, is not a sign of fundamental weakness but rather a proactive measure by a market leader to adapt to evolving economic realities and ensure its continued competitive edge and financial health for decades to come.
Analyst Reactions and Future Implications
Market analysts are closely monitoring Demant’s restructuring, viewing it as a strategic recalibration rather than a crisis. The decision to undertake significant job cuts and operational streamlining, while difficult, is generally perceived as a necessary step to protect margins and enhance shareholder value in a challenging economic climate. The clear communication regarding the protection of U.S. customer-facing roles is particularly important for maintaining market confidence and ensuring uninterrupted service for hearing care professionals. The successful execution of this plan could set a precedent for other industry players facing similar pressures. The implications suggest a leaner, more agile Demant, better positioned to capitalize on future market recovery and continued innovation in hearing technology. The company’s focus on long-term structural changes, rather than short-term fixes, signals a strategic vision for sustained profitability.
In conclusion, Demant’s comprehensive cost reduction program, including 700 job cuts, marks a pivotal moment for the Danish hearing healthcare giant. Driven by a turbulent year of macroeconomic uncertainties and reduced profitability, these measures are designed to reset the company’s cost base and secure its financial health for the future. While the impact will be felt globally, particularly in administrative functions, Demant has explicitly reassured the U.S. hearing care market that essential professional services will remain unaffected. With a conservative yet optimistic outlook for market growth and significant contributions expected from its strategic initiatives and recent acquisitions, Demant is strategically positioning itself to navigate the current economic headwinds and emerge as a more efficient and profitable leader in the global hearing solutions industry.